Circio Holding ASA

Report Publication Announcement • Mar 19, 2025

Circio invites to corporate update webcast on 26 March 2025

Circio invites to corporate update webcast on 26 March 2025

· CEO Dr. Erik D Wiklund will provide a general company update and present the

most recent circVec experimental data and R&D strategy

· CFO Dr. Lubor Gaal will present the 2024 financial results (unaudited) and

provide an update on Circio´s corporate development activities

Oslo, Norway 19 March 2025 - Circio Holding ASA (OSE: CRNA), a biotechnology

company developing powerful circular RNA technology for next generation nucleic

acid medicine, invites to a live webcast at 10:00am CET on Wednesday 26 March

2025. In the webcast, Circio management will provide a corporate update and

present the latest developments for the circVec platform technology.

The webcast will include an overview of ongoing testing with the novel circVec

3.0 generation, AAV and non-viral gene therapy vector development, and tissue

-specific circVec expression data in vivo, as well as an outlook on experimental

plans and milestones.

The corporate section will cover Circio´s 2024 financial results (unaudited) and

provide an update on financing and business development activities for 2025.

Presenters:

CEO Dr. Erik Digman Wiklund

CFO Dr. Lubor Gaal

Time: 10:00 CET on 26 March 2025

click here to access the Teams webcast (https://teams.microsoft.com/l/meetup

-join/19%3ameeting_ZmVlODI4ZTktZDFmMC00MjliLWFmNDItMDA5NTJkZjdlMGQ1%40thread.v2/0

?context=%7b%22Tid%22%3a%2266b0661a-3ec3-48a8-a966

-5b0cce82b3fe%22%2c%22Oid%22%3a%223f5f84b0-5521-4c04-bd8a-e185546abe04%22%7d)

Meeting ID: 392 868 593 190

Passcode: Mn7uS2qQ

Participate by phone:

+47 21402155

Phone conference ID: 394 288 903#

Questions can be submitted in advance by email to Erik D Wiklund:

erik.wiklund@circio.com or directly in the live webcast

A recording of the webcast will be made available on the Circio

webpage (http://www.circio.com/)

For further information, please contact:

Erik Digman Wiklund, CEO

Phone: +47 413 33 536

Email: erik.wiklund@circio.com

Lubor Gaal, CFO

Phone: +34 683 343 811

Email: lubor.gaal@circio.com

About Circio

Building next generation RNA technology for nucleic acid medicine

Circio Holding ASA is a biotechnology company developing powerful circular RNA

vector expression technology for next generation nucleic acid medicine.

Circio has established a unique circular RNA (circRNA) vector expression

platform for novel DNA, RNA and viral therapeutics. The proprietary circVec

technology is based on a modular genetic cassette design for efficient

biogenesis of multifunctional circRNA inside cells, which can be deployed in

multiple therapeutic settings, including genetic medicine, cell therapy and

chronic disease. The circVec platform has demonstrated up to 15-fold enhanced

and more significantly more durable protein expression vs. classic mRNA vector

systems and has the potential to become a new gold-standard platform technology

for nucleic acid and viral therapeutics in the future. The circRNA R&D

activities are being conducted by the wholly owned subsidiary Circio AB based at

the Karolinska Institute in Stockholm, Sweden.

In addition, Circio is developing a pan-RAS cancer vaccine, TG01, targeting KRAS

driver mutations. TG01 is currently being tested in two clinical trials: RAS

-mutated pancreatic and lung cancer in the USA and multiple myeloma in Norway.

These studies are being run through academic and industry collaborative

networks, supported by prestigious research grants from Innovation Norway and

the Norwegian Research Council, creating read-outs and future optionality for

the program at low cost to Circio.